Altimmune ALT Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -42.7%+14.5pp | -50.6%+9.3pp | -52.6%+20.3pp | -55.9%+7.4pp | -57.3%-2.8pp | |
| Return on assets | -37%+15.3pp | -42%+12.3pp | -45.8%+20.0pp | -48.3%+8.6pp | -52.2%-2.8pp | |
| Return on invested capital | -61.7%+43.0pp | -62%+77.6pp | -74.6%+55.4pp | —— | -104.6%+19.4pp | |
| Liquidity | ||||||
| Current ratio | 29.6×+13.7× | 18.5×+5.4× | 17.2×+0.3× | 20.4×+9.1× | 15.8×-0.7× | |
| Quick ratio | 29.6×+13.7× | 18.5×+5.4× | 17.2×+0.3× | 20.4×+9.1× | 15.8×-0.7× | |
| Cash ratio | 8.6×+3.6× | 2.9×-0.6× | 4.9×+1.2× | 19.9×+16.1× | 5×-2.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×+0.1× | 0.2×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0×0.0× | |
| Debt-to-assets | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0×0.0× | |
| Interest coverage | -35.9×+10,874× | -57.8×+11,406× | -118.9×+11,074× | -346.9×+2,977× | -10,910.3×-7,941× | |
| Per Share | ||||||
| Book value per share | $2.28+21.3% | $2.55+46.7% | $2.08+10.6% | $1.98-7.9% | $1.88-23.0% | |
| Valuation | ||||||
| Market capitalization | $558.14M-2.1% | $376.68M-26.5% | $332.73M-23.8% | $583.16M+23.7% | $385.07M-46.5% | |
| Enterprise value | $495.27M-5.0% | $368.56M-22.8% | $286.14M-29.6% | $414.58M-0.4% | $336.17M-47.6% | |
| Price / book | 2×-2.0× | 1.7×-2.5× | 1.8×-1.5× | 3.6×+0.5× | 2.7×-1.5× | |
| Earnings yield | -16.3%-0.5pp | -23.4%-4.8pp | -25.2%-1.5pp | -15%+6.4pp | -23.4%-10.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Altimmune's ratios come from?
- Every ratio is computed from Altimmune's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
